sulperazone has been researched along with Cross Infection in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mitrokhin, SD | 1 |
| Bachinskaia, EN; Beloborodova, NV; Kuznetsova, ST; Popov, DA; Vostrikov, TIu | 1 |
| Cheong, YM; Lim, VK | 1 |
4 other study(ies) available for sulperazone and Cross Infection
| Article | Year |
|---|---|
[Sulperazone in the treatment of severe infections in patients with cancer].
Topics: Anti-Bacterial Agents; Cefoperazone; Cross Infection; Drug Combinations; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Neoplasms; Pneumonia, Bacterial; Sulbactam; Surgical Wound Infection; Urinary Tract Infections | 2003 |
[Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].
Topics: Adult; Anti-Bacterial Agents; Cefoperazone; Child; Child, Preschool; Cross Infection; Drug Combinations; Gram-Negative Bacteria; Humans; Infant; Male; Middle Aged; Postoperative Complications; Sulbactam | 2005 |
[Three-year experience with the use of cefoperazone/sulbactam (sulperazone) in the treatment of hospital-acquired infections in an oncologic hospital].
Topics: Anti-Infective Agents; Candida; Cefoperazone; Cross Infection; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Oncology Service, Hospital; Sulbactam | 2006 |
In-vitro activity of cefoperazone-sulbactam combination against cefoperazone resistant clinical isolates in a Malaysian general hospital.
Topics: Cefoperazone; Cephalosporin Resistance; Cross Infection; Drug Combinations; Gram-Negative Bacterial Infections; Hospitals, General; Malaysia; Sulbactam | 1995 |